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Microporous Biodegradable Films Promote Therapeutic
Angiogenesis
Eseelle K. Hendow, Mehran Moazen, Francesco Iacoviello, Laurent Bozec,
Caroline Pellet-Many, and Richard M. Day*
Peripheral arterial disease and critical limb ischemia are common symptoms
of cardiovascular disease. Vascular surgery is used to create a bypass around
occluded blood vessels to improve blood flow to ischemic muscle, thus
avoiding the need for amputation. Attempts to vascularize tissues by
therapeutic angiogenesis using delivery of exogenous angiogenic agents are
underwhelming. A material-based approach that provides an endogenous
stimulus capable of promoting angiogenesis and increased tissue perfusion
would provide a paradigm shift in treatment options available. It is reported
here that microporous biodegradable films produced using thermally induced
phase separation provide a localized biophysical stimulus of proangiogenic
genes in vivo that is associated with increased blood vessel density and
restoration of blood flow to ischemic tissue. These findings show, for the first
time, that acellular, nonfunctionalized biodegradable biomaterials can provide
an innovative, material-based approach for therapeutic angiogenesis to
enhance tissue reperfusion in vivo.
1. Introduction
Peripheral arterial disease (PAD) is often caused by the build-up
of atherosclerotic fat in the arteries, which, if left untreated, can
develop into limb ischemia and other forms of cardiovascular
disease.[1 ] PAD is becoming more prevalent with over 200 mil-
lion people affected worldwide as a result of an ageing population
and an increase in obesity.[2 ] Currently there is no curative treat-
ment for PAD. Therefore, there is a clear need for new therapeu-
tic strategies to promote angiogenesis capable of vascularizing
ischemic tissue.
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Researchers have strived to achieve im-
proved vascularization of ischemic tissue
using strategies that involve delivery of an-
giogenic growth factors, cell therapy, and
gene therapy. Preclinical studies investigat-
ing the delivery of angiogenic growth fac-
tors, such as vascular endothelial growth
factor (VEGF), platelet-derived growth fac-
tor (PDGF), and fibroblast growth fac-
tor (FGF), to increase vascularization have
been encouraging but these results have not
been translated into clinical efficacy.[3 ] Rea-
sons for the lack of stabilization and mat-
uration of newly formed blood vessels, vi-
tal for clinical efficacy, include diffusion of
the therapeutic agent from the target site,[4 ]
or rapid degradation of peptide growth fac-
tors rendering them ineffective (for exam-
ple, VEGF has a half-life in vivo of ≈30
min).[5 ] Gene therapy has been explored for
sustained release of angiogenic factors in
patients with PAD;[6 ] however, concerns have been raised regard-
ing the risk of oncogenic effects with this approach.[7 ] Moreover,
delivery of proangiogenic agents, either as proteins or genes, in
the formofmonotherapy does not replicate the plethora of factors
that underlie the physiological process of angiogenesis in vivo,
where a complex interplay of factors from different cell types is
required to form stable blood vessels.[8 ] Alternative approaches
involving delivery of cells capable of providing a proangiogenic
secretome are faced with similar challenges, including cell re-
tention and survival at the implant site.[9–11 ] Attempts to refine
the delivery process using combination products, consisting of
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materials combined with angiogenic agents, to provide more tar-
geted and sustainedmodes of delivery have achieved only limited
success.[12–14 ]
A more robust therapeutic response might be achieved by
identifying stimuli capable of triggering a biological response
that results in the plethora of angiogenic factors capable of
achieving functional tissue vascularization. We propose this ap-
proach could be achieved using synthetic materials exhibiting
optimal structural and mechanical properties. Evidence to sup-
port the feasibility of this approach exists from previous work
that has indicated biophysical cues controlling features of the
local microenvironment, such as defined stiffness[15 ] and mate-
rial topography,[16 ] are important regulators of cell behavior, in-
fluencing cell proliferation and differentiation,[17 ] macrophage
fusion,[18 ] and secretion of soluble cytokines.[19 ] However, to date
there is a paucity of data demonstrating translation of these ef-
fects in physiological in vivo environments and/or evidence of
therapeutic angiogenesis in ischemic tissue. Recently, activation
of angiogenesis and formation of microvasculature in vivo have
been reported with injectable amorphous hydrogels exhibiting
varying stiffness.[20 ] Similarly, amorphous materials consisting
of natural polymer gels, including fibrin and extracellular ma-
trix (ECM)-derived hydrogels, as well as highly porous gelatin
films, have been reported to result in processes associated with
angiogenesis.[12,21–23 ] Taken together these results suggest me-
chanically defined microenvironments created by implanting
materials could be exploited to deliver local stimuli that translate
into proangiogenic signals, providing new approaches for deliv-
ering therapeutic angiogenesis.
Here we show, for the first time, that the topographic features
of a biodegradable material can be utilized to achieve therapeu-
tic angiogenesis capable of restoring perfusion of ischemic tissue
in vivo via stimulation of endogenous angiogenic factors that re-
sult in increased tissue vascularization. In this pilot study, the ef-
fect is achieved using the biodegradable synthetic polyestermate-
rial, poly(d,l-lactide-co-glycolide) (PLGA), widely used in existing
medical devices, such asmeshes and sutures, that have been pro-
cessed via thermally induced phase separation (TIPS) to create
micropored topographical features. We have previously demon-
strated that TIPS-processed materials with other geometries pro-
vide an excellent substrate for cell attachment in vitro and be-
come rapidly with host tissue when implanted subcutaneously
into soft tissues.[24,25 ] However, to achieve an efficacious thera-
peutic angiogenic effect, the response associated with the ma-
terial needs to provide sufficient neovascularization capable of
restoring tissue perfusion. In order to evaluate the level of an-
giogenic potency, the current study used multiple methods to in-
vestigate the in vivo angiogenic effect of TIPS-processed PLGA
polymer films in ischemic tissue.
2. Results and Discussion
TIPS is a widely used technique for the fabrication of 3D poly-
meric tissue scaffolds with a range of geometries.[26,27 ] TIPS
has also been used extensively for the preparation of porous
membranes and films from a variety of polymers, including
poly(vinylidene fluoride) (PVDF), polyethylene, polypropylene,
poly(methyl methacrylate), polystyrene, and poly(ethylene-co-
vinyl alcohol),[28–33 ] for applications including filtration, quasi-
solid electrolytes for electrical devices, and dermal tissue engi-
neering scaffolds.[34,35 ] The current study is the first to investigate
the use of TIPS films composed of PLGA specifically for use in
therapeutic angiogenesis.
Surface analysis of polymer films using scanning election mi-
croscopy (SEM) revealed the TIPS films exhibited an open porous
surface with the polymer organized into a network of differently
sized ridges and struts, interspersed by interconnected pores
(Figure 1b). The porous structure was formed when the temper-
ature of a thin film of polymer solution was lowered by quench-
ing in liquid nitrogen, resulting in de-mixing of the homoge-
neous polymer solution into a polymer-rich and a polymer-lean
phase.[36 ] Subsequent lyophilization of the frozen polymer film
removed the frozen solvent, leaving behind the porous polymer
structure. Micro-computed tomography (CT) revealed a microp-
orous structure was present throughout the entire thickness of
the films (Figure 1c), with an estimated total porosity of ≈58%.
The normal distribution of pore size throughout the film ranged
from ≈450 nm to 5 µm, with a median value of 2.676 µm (Fig-
ure 1d). The control films used in the study were solid and did
not contain any micropores.
A key feature of PLGA that has led to its widespread clinical
use is its ability to undergo degradation by hydrolysis, resulting
in monomers of lactic and glycolic acids that are metabolized
and excreted from the body.[37 ] Simulated physiological degrada-
tion of the TIPS polymer films in an aqueous in vitro environ-
ment resulted in a loss of surface porosity and roughness com-
paredwith the dry startingmaterial (Figure 1e,f), which coincided
with a progressive reduction in elastic modulus of the material
from 33.2 ± 2.2 to 1.37 ± 2.8 MPa over the 21 days of simulated
degradation (Figure 1g). When the TIPS polymer film undergoes
simulated degradation in vitro, the polymer becomes softened
due to plasticization, as indicated by the reduction in mechani-
cal strength shown in Figure 1g. Previous studies by Blaker et al.
have suggested plasticization of the TIPS polymer matrix and as-
sociated loss of mechanical properties of the polymer led to dis-
tortion of the porous structure of highly porous poly(d,l-lactide)
composite foams at the microlevel resulting in collapse of pore
walls and loss of ordered pore structure.[38 ] In the current study,
it is likely that a similar mechanism accounts for the progressive
loss of pores observed in the TIPS films as they underwent simu-
lated degradation in vitro. A comparison of the mechanical prop-
erties of TIPS films versus solid films composed of the same poly-
mer has not previously been reported but previous studies sug-
gest the presence of pores in the polymer films is likely to influ-
ence their mechanical properties during degradation. A compar-
ison between PLGA TIPS scaffolds and salt-leached scaffolds re-
ported differences in mechanical strength, with the thicker poly-
mer walls of the salt-leached scaffold having reduced mechanical
strength attributed to an autocatalytic hydrolysis effect.[39 ]
Following initial in vitro evaluation, the proangiogenic proper-
ties of the TIPS polymer films and their ability to restore blood
perfusion in ischemic tissue in vivo were compared with con-
trol nonporous films composed of the same polymer. Each type
of material was overlaid onto the site of vascular occlusion cre-
ated using an established preclinical model of PAD that results in
hind limb ischemia.[40–42 ] The level of hind limb blood perfusion
following vascular occlusion and treatment, assessed using Laser
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Doppler imaging at weekly intervals over 21 days, was signifi-
cantly increased at day 14 and day 21 in the group receiving TIPS
polymer films compared with either the group receiving control
nonporous polymer films or the group receiving no treatment fol-
lowing vascular occlusion (p< 0.0001;Figure 2a,b). At day 14 after
ligation, themean perfusion ratio value for the TIPS polymer film
group was 0.691± 0.180 compared with 0.270± 0.140 in the con-
trol nonporous film group and 0.267 ± 0.115 in the no treatment
group. At day 21 after vascular occlusion, the mean perfusion ra-
tio value for the TIPS polymer film group was 0.818± 0.172 com-
pared with 0.251 ± 0.093 in the control nonporous film group
and 0.267 ± 0.038 in the no treatment group. These data indicate
that at timepoints beyond 7 days postvascular occlusion, TIPS
polymer films have the potential to stimulate angiogenesis and
restore vascular perfusion to a level that is close to that of the un-
treated control limb at day 21. In contrast, vascular perfusion in
the group receiving the nonporous control films remained close
to that of the group receiving no treatment postvascular occlu-
sion, where the level of perfusion did not increase between day 7
and day 21 postligation.
At day 21, tissues surrounding the implanted materials at the
site of vascular occlusion were explanted and analyzed for puta-
tive mechanisms that could account for the increased blood flow
associated with treatment using TIPS polymer films.Histological
analysis of the explanted tissue revealed functional restoration of
tissue perfusion corresponded with an increase in blood vessel
density in the tissue surrounding the TIPS polymer films com-
pared with the blood vessel density observed in the tissue sur-
rounding the control nonporous polymer films (Figure 2c,f,g).
Erythrocytes were visible within the lumen of the vessels indi-
cating that the new vessels were patent and functioning, which
would contribute to an increased flux value from moving red
blood cells in the vasculature recorded in the Doppler imaging.
The increased vascularization associated with the TIPS poly-
mer films indicates that the TIPS-fabricated film elicits a particu-
lar proangiogenic host response compared with nonporous poly-
mer films composed of the same material. It is therefore reason-
able to propose that the physical features of the porous TIPS films
account for the differential angiogenic response observed rather
than a nonspecific angiogenic response associated with a foreign
body reaction due to the implantation of polymer material per
se. Multinucleated giant cells were more evident at the interface
between the host tissue and the implanted TIPS polymer films
(Figure 2d). Fusion ofmacrophages to formmultinucleated giant
cells is a phenomenon often associated with materials implanted
for longer periods of time.[43 ] The inflammatory cell infiltrate
associated with a foreign body reaction arising from degradable
materials, such as that observed with the PLGA TIPS films, is
transient, self-limiting, and resolves once thematerial completely
degrades.[44,45 ] This is essential to avoid the onset of chronic
inflammation and fibrosis associated for devices intended for
therapeutic purposes. The phenotype(s) of the macrophages
surrounding the implanted films is likely to be influenced by
the structural features of the material and may provide further
insight into the mechanisms underlying the functional improve-
ment in vascularization observed. Of particular relevance is the
influence of the porous structure of the TIPS films. Porosity has
previously been shown to affect macrophage polarization, with
cells outside porous implants found to have a predominantly
regenerative M2 phenotype associated with secretion of proan-
giogenic factors.[45 ] Porosity of materials has been identified
as a key determinant of angiogenesis in surrounding tissues.
For example, nondegradable polytetrafluoroethylene (PTFE)
membranes containing pores large enough for host cell penetra-
tion (0.8–8 µm) were associated with a higher number of blood
vessels compared with the same material exhibiting smaller
(0.02 µm) pores.[46 ] Likewise, cardiac implantation of sphere-
templated, poly(2-hydroxyethyl methacrylate-co-methacrylic
acid) (pHEMA-co-MAA) hydrogel scaffolds with larger pore di-
ameters (40–80 µm) was associated with an angiogenic response
when implanted into the myocardium of immunocompetent
rats, which coincided with macrophage polarization toward
M2 phenotype.[47 ] Multinucleated giant cell infiltration into the
implanted material was only observed with the TIPS polymer
films due to the lack of porosity in the control film. Further inves-
tigation is required to establish whether particular macrophage
phenotype(s) plays a key role in the increased vascularization and
tissue perfusion observed and how this is influenced by changes
to the physical properties of the material as it degrades over
time. It is likely that the angiogenic response to the implanted
material arises from a coordinated interaction of multiple cell
types within the local environment. This includes not only
macrophage subtypes that release key factors involved in angio-
genesis and chemotaxis, but also pericytes and endothelial cells
required for vascular remodeling, as suggested elsewhere.[48 ]
The impact of disease on the angiogenic response observed
should also be considered, since the current study used healthy
animals with treatment implemented immediately after the on-
set of ischemia. Ideallymodels used for further in vivo testingwill
reflect comorbidities associated with a chronic ischemic state to
Figure 1. a) Macroscopic image of nonhydrated TIPS film at day 0. b) Scanning electron microscopy (SEM) of TIPS film surface at day 0. c) Volume
rendering of TIPS film pore space at day 0 using micro-CT (calculated porosity 58%). d) The frequency of the pore size (µm) distribution and percentage
frequency of pores in the TIPS film at day 0 were measured from the micro-CT scans. e) SEM images of TIPS and control nonporous films undergoing
simulated physiological degradation in vitro at days 0, 1, 4, 7, 10, and 21 showing the change in surface topography as thematerial degrades via hydrolysis
(scale bar: 1 µm). f) Quantification of changes in the area of pores in the TIPS films undergoing simulated physiological degradation in vitro was analyzed
in SEM images using ImageJ software. Data were analyzed using one-way ANOVA with Tukey’s multiple comparisons tests. Significant differences were
detected between pore area at day 0 and subsequent timepoints (p < 0.001). g) Average roughness measurements of TIPS and control nonporous films
undergoing simulated physiological degradation in vitro acquired using atomic force microscopy (AFM) at days 0 and 10. Three to five 50 µm × 50 µm
areas per sample were imaged at 512 × 512 pixels. From these images, the average roughness values in nanometer were obtained using JPK analysis
software source (JPK Instruments, Germany). Data were analyzed using Mann–Whitney test between days 0 and 10 for each type of film (*** p < 0.001,
**** p < 0.0001). h) Young’s modulus of TIPS film and control nonporous films undergoing simulated physiological degradation in vitro at days 0, 10,
and 21 was calculated using the Oliver–Pharr method from indentation curves measured through nanoindentation. Data were analyzed using two-way
ANOVA with Tukey’s multiple comparisons tests. Significant differences were detected within each group for all timepoints (p < 0.0001), except between
day 0 and day 10 control films. Significant differences were detected between TIPS films and control films at each time point (p < 0.0001), except at day
21.
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ascertain whether the angiogenic effect observed is replicated in
scenarios that reflect more closely clinical disease.
To identify potential mechanisms that may account for the
differences in angiogenesis observed in vivo between the im-
plantedmaterials, relative levels of angiogenic growth factor gene
expression in tissue collected from the implant site were com-
pared from the different experimental conditions. Several proan-
giogenic genes were upregulated in the explanted tissue con-
taining the TIPS film compared with tissue containing the con-
trol nonporous polymer films (Figure 3). These included CD55,
Egfl7, epiregulin (Ereg), FGF 2, Hey2, kinase insert domain re-
ceptor (KDR; also known as vascular endothelial growth factor
receptor 2), leptin (LEP), neurotrophic tyrosine kinase receptor
type 2 (Ntrk2), PDGF-B, placental growth factor (PGF), plasmino-
gen (PLG), QK peptide (QK), RAS p21 protein activator 1(RASA-
1), Stablin (STAB)1, VEGF-A, and tryptophanyl-tRNA synthetase,
mitochondrial (WARS2), all factors that are associated with con-
trolling key stages of angiogenesis, including blood vessel mor-
phogenesis and vasculogenesis.[49–63 ] Conversely, the relative ex-
pression of certain genes that control factors that contribute to
inhibition of angiogenesis was lower in tissues collected from
the TIPS polymer film group compared with the control non-
porous polymer film group. These included brain-specific angio-
genesis inhibitor 1 (BAI1), type IV collagen 훼3 (COL4A3), Serpin
E1, tissue inhibitor of metalloproteinases (TIMP)-3, TIMP-4, and
Troponin I3 (TNNI3).[64–69 ] While the gene array employed in the
current study focused on the expression of angiogenic growth fac-
tors, future studies should also pay attention to the role of the host
immune response to the implanted material in regulating angio-
genesis, which could include extending the gene analysis to the
immune-response mediated by macrophages. The current study
lacks a definitive mechanistic connection between pore architec-
ture and increased angiogenesis. Further in vivo studies using
appropriate knockout models or agents capable of blocking spe-
cific pathways associated with angiogenesis and/or the immune
response are necessary to interrogate the mechanistic relation-
ship between porosity and angiogenesis. Future studies will also
enable better understanding of the stability and remodeling of
newly formed vessels and how this corresponds with degradation
of the material overtime.
Nevertheless, the findings in the current study support the
concept that materials can be designed to beneficially manip-
ulate the foreign body reaction to achieve a physiological re-
sponse that can be used to therapeutic effect.[70–72 ] Unlike exist-
ing biological-based approaches that involve delivery of individ-
ual proteins or genes, either as a single or combined entity, neo-
vascularization observed in the current study results from the ac-
tivation and secretion of a combination of proangiogenic gene
factors from cells that interact with the microporous material.
The observed increase in expression of multiple gene-associated
angiogenesis indicates the TIPS polymer film elicits a polygenic
response that simulates more closely the natural process of an-
giogenesis that results in the formation of stable and functional
vasculature.
Microporous scaffolds composed of other materials such as
bioceramics, decellularized extracellular matrix, and microchan-
neled 3D-printed scaffolds have also been associated with a
proangiogenic effect.[73–75 ] However, in contrast to the current
study, these materials have been designed with features primar-
ily intended for other applications, such as accelerating osteoge-
nesis. Moreover, unlike the current investigation, these studies
have not reported whether the angiogenesis observed in response
to their materials is of therapeutic value and capable of restora-
tion of blood flow in ischemic tissue. The authors are unaware of
any previous reports involving the use of similar acellular, non-
functionalized, porous polymer films that have achieved a similar
therapeutic angiogenic response.
Since the PLGA TIPS polymer material degrades over time,
further investigation is necessary to establish the duration of the
proangiogenic response andwhether changes in the stiffness and
porosity of the material observed in vitro contribute to the re-
sponse observed in vivo. Furthermore, since the TIPS process is
highly versatile, the method used to produce films in the current
study provides scope to produce polymer films that exhibit differ-
ent roughness and pore structures via adjustment of parameters
including the polymer:solvent ratio, composition of PLGA (ratio
of lactide to glycolide), solvent, and rate of quenching.[27 ] The abil-
ity to control these parameters through further refinement of the
porous films provides greater opportunity to fine tune the proan-
giogenic effect achieved compared with other approaches inves-
tigated for therapeutic angiogenesis, such as gene-based therapy,
thus lowering concerns over oncogenic risks. This provides scope
for future studies aimed at elucidating optimal properties of the
porous polymer films for regulating therapeutic angiogenesis.
The stability of the dry, preimplanted TIPS polymer films com-
posed of PLGA, together with the relatively simple manufactur-
ing process, provides an opportunity for low-cost, “off-the-shelf
products” that are compatible with long-term storage. In addi-
tion to PAD, TIPS polymer films may have potential use in the
treatment of other forms of cardiovascular disease, e.g., cardiac
Figure 2. a) Laser Doppler imaging of the paws of mice that had undergone unilateral femoral artery ligation and subsequent implantation of TIPS films,
control nonporous films, or received no treatment after ligation. Doppler images were acquired immediately after surgery (day 0) and at days 7, 14, and
21. b) Quantification of laser Doppler imaging of the paws of mice that had undergone unilateral femoral artery ligation and subsequent implantation
of TIPS films, control nonporous films or no treatment after ligation. Data are presented as the perfusion ratio at days 7, 14, and 21 relative to the
perfusion in the contralateral control limb (n = 3 per group). Data were analyzed using two-way ANOVA with Tukey multiple comparisons testing (****
p < 0.0001.) c) Hematoxylin and eosin (H&E) staining of tissue sections collected from the hind limb ischemia model containing the implanted TIPS
polymer film at day 21. Cells can be seen infiltrating the porous structure of the TIPS film (arrowheads). A band of cells (denoted by the double-headed
arrow) appears to have migrated into the porous structure of the TIPS film. d) Higher magnification of an area of the TIPS film shows cells (arrowheads)
infiltrating aligned channels perpendicular to the surface of the film. A cluster of macrophages at the interface between the film and the host tissue
have formed multinucleated giant cells. e) H&E staining of the control nonporous film at day 21. The band of inflammatory cell infiltrate surrounding
the implanted material appeared to be less dense compared with the TIPS film. f) Von Willebrand factor (VWF) staining of blood vessels (arrowheads)
in tissue surrounding the implanted TIPS film. g) Quantification of the number of blood vessels positively stained for VWF in tissue surrounding the
implanted TIPS film and control nonporous film at day 21. The number of vessels was counted by three independent observers. (n = 5mice per group;
five fields of view per sample. Data analyzed using Mann–Whitney test; *** p < 0.001.)
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Figure 3. Heat maps illustrating the relative expression of pro- and antiangiogenic growth factor genes that exhibited a >0.5-fold change in expression
in tissue collected from the hind limb ischemia model at the site of implantation of the TIPS film or control film at day 21 normalized to nontreatment
control.
patches for treatment of ischemia or films for dermal wounds
and ulcers.
3. Conclusion
This study provides compelling evidence to support the concept
that microporous TIPS films are capable of stimulating a range
of proangiogenic genes in vivo that provide a favorable local envi-
ronment for neovascularization, increased tissue perfusion, and
therapeutic angiogenesis in ischemic tissue. These findings pave
the way to establishing new material-based strategies to achieve
therapeutic angiogenesis.
4. Experimental Section
Preparation of TIPS Polymer Films: PLGA 7507 (PURASORB PDLG
7507; 75:25 dl-lactide/glycolide copolymer; inherent viscosity, 0.70 dL g−1,
Corbion Biomaterials, Gornchem, Netherlands) was dissolved in dimethyl
carbonate (DMC) (anhydrous >99%, Sigma–Aldrich, UK) (10 wt%). So-
lutions were mixed for 18 h at room temperature. 13 mm diameter
0.16mm thick D263M borosilicate cover glasses (VWR, UK) were coated
in the polymer solution by holding individual coverslips with forceps and
manually submerging them into the polymer solution. Excess solution
was displaced by blotting the edge of the coverslip on a paper towel. The
polymer-coated coverslips were immediately horizontally immersed into
liquid nitrogen to achieve thermally induced phase separation. The frozen
samples were transferred to a −80 °C freezer before being transferred to a
freeze–dryer (Edwards Modulyo, Edwards, UK). Once under vacuum, the
samples were lyophilized for 18 h to allow the sublimation of residual DMC
from within the material.
Preparation of Control Polymer Films: 13 mm diameter borosilicate
cover glasses were dip-coated with PLGA 7507 polymer dissolved in DMC
(10 wt%) and placed onto Parafilm to air-dry over 72 h in a fume hood.
Hydration of TIPS Polymer and Control Polymer Films: TIPS polymer
films and control polymer films were hydrated by placing individual films
into the wells of an ultralow attachment 24-well plate (Corning Costar)
containing 0.5 mL ethanol (7% v/v) in phosphate-buffered saline (PBS).
The plate was placed on a plate shaker and incubated at 37 °C with gentle
agitation for 12 h. The ethanol solution was removed, and the films were
washed in 1mL PBS prior to further use.
Simulated Degradation In Vitro: Hydrated TIPS and control polymer
films were transferred to sterile ultralow attachment 24-well plates and in-
cubated in 1 mL PBS at 37 °C for 1, 4, 7, 10, and 21 days. The degraded
samples were dried in a desiccator prior to ultrastructural analysis. PBS
was used for the degradation study in accordance withmedia used in stan-
dardized degradation studies (ISO 10993–9).
Ultrastructural Imaging of the Polymer Films: SEM was used to exam-
ine ultrastructural features of the polymer films degraded under simulated
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physiological conditions. The samples were mounted onto aluminum
stubs using carbon sticky tabs and sputter-coated with gold/palladium
alloy in an argon atmosphere. Samples were imaged using a Jeol 7401
high-resolution field emission SEM. The area of the pores in the degraded
TIPS films was measured from SEM images (n = 3) using image analysis
software (ImageJ 1.52a).
X-ray micro-CT was used to analyze the internal structure of the TIPS
films using a ZEISS Xradia 520 Versamicro-CT system (Carl Zeiss X-rayMi-
croscopy Inc., Pleasanton, CA, USA). A 5mm circular segment of the TIPS
film was collected using a disposable biopsy punch. An area of 510 µm ×
510 µm of the TIPS film was scanned acquiring 1401 projections and 57 s
exposure time with camera binning set at 1. The X-ray tube was operated
at 40 kV and 3 W, employing the 20× objective lens in order to achieve a
voxel size of 223 nm.
A filtered back projection algorithm (FDK) was used to reconstruct the
radiographs into a 3D volume using the Zeiss proprietary image recon-
struction software package (Zeiss MReconstructor, Carl Zeiss X-ray Mi-
croscopy Inc., Pleasanton, CA, USA).
Data visualization and segmentation were performed with Avizo soft-
ware (Thermo Fisher Scientific, France). A 500 × 500 × 500 voxel
(111 × 111 × 111 µm) volume was extracted in order to avoid artifacts
at the edge of the scan and to maximize the contrast between pore and
polymer phases during the segmentation process. The grayscale images
were subsequently segmented into a binary dataset assigning pixels to the
pore phase and to the polymer film by the way of a thresholding procedure.
FiJi software package was used on the binarized datasets for computing
local thickness values and average pore size distribution.[76 ]
Surface Texture Analysis of the Polymer Films: Atomic force microscopy
(AFM) was used to measure the surface roughness of the polymer films
undergoing in vitro simulated physiological hydrolytic degradation. The
polymer films were hydrated before incubation in 1 mL PBS at 37 °C for
1, 4, 7, and 10 days. Surface analysis of the hydrated (or dry control) films
was performed using a Bruker Nanowizard IV atomic force microscope
(Bruker, Santa Barbara, CA, USA) fitted with a Respa-10 etched silicone
probe or anMSNL-10 6 cantilever 0.01–0.5Nm−1 sharp nitride level probe
(Bruker, Coventry, UK). An area covering 50 µm × 50 µmwas measured at
a resolution of 512 × 512 pixels, with 3–5 scans per sample. The average
roughness (Ra) value was calculated (JPK analysis software; JPK Instru-
ments, Germany) prior to any image processing.
Stiffness of the Polymer Films: The mechanical properties of the poly-
mer films undergoing in vitro simulated physiological hydrolytic degrada-
tion were characterized using an Anton Paar Bioindenter (UNHT³ Bio; An-
ton Paar, Austria) fitted with a Berkovich diamond tip. The polymer films
(dry control films or films hydrated in PBS) were fixed onto a polystyrene
Petri dish, and measurements were conducted at room temperature. Four
indentation measurements were performed on each sample at intervals
of 50 µm apart. A loading rate of 30 mN min−1 with a maximum loading
rate of 5mNwas used with a 5 s hold. The elastic modulus was calculated
from indentation curves using the Oliver–Pharr method.[77 ]
In Vivo Assessment of Polymer Films in Ischemic Tissue: Circular sam-
ples (5mmØ) of the polymer films for implantation were created using a
biopsy punch. The films were hydrated, washed with 1mL PBS and placed
into one PBS prior to implantation. Hind limb ischemia was induced in fe-
male 2–3month old c57bl/6mice by unilateral femoral artery ligation.[78 ]
Briefly, under general anesthesia (O2 flow meter at 1 L min−1 and isoflu-
rane to 1.5%), an incision along the center of the medial left thigh was
made using fine scissors. The common femoral artery was exposed and
isolated from the femoral vein and nerve. The artery was then ligated with
a triple suture, proximally to the deep femoral artery bifurcation. Immedi-
ately following artery ligation, the polymer films were placed over the oc-
cluded vessel bundle. Bupivacaine analgesia was administered intramus-
cularly before the wound was closed. Vessel occlusion was confirmed by
laser Doppler imaging (moorVMS-LDF, Moor Instruments, UK) immedi-
ately after surgery, with furthermeasurements of tissue perfusion recorded
at weekly intervals to day 21. Tissue perfusion in the ischemic limb was
normalized against the control contralateral limb of each animal. At day
21 following surgery, the mice were euthanized by overdose of CO2, fol-
lowed by cervical dislocation, and the leg muscles from the test site and
contralateral control limb were harvested for analysis. All experiments
were performed under a UK Home Office license (PLN: 70/7700), in com-
pliance with the 1986 United Kingdom Home Office Animals (Scientific
Procedures) Act and with the approval of the University College London
local ethics committee.
Qiagen RT2 Angiogenic Growth Factors Array (Qiagen, UK) was used
to profile gene expression of angiogenic-related growth factors from tissue
surrounding the implanted TIPS film or control polymer film, or tissue col-
lected from nontreated controls. About 10–30mg of tissue was mechani-
cally homogenized and RNA extracted usingMonarch Total RNAMiniPrep
Kit (Monarch, UK) in accordance with the manufacturer instructions. RNA
concentration and purity were measured using a NanoDrop 8000 UV Visi-
ble Spectrophotometer (ThermoScientific, UK). To create complementary
DNA (cDNA) from the extracted RNA and eliminate genomic DNA, the
RNA was reverse-transcribed using QuantiTect Reverse Transcription Kit
(Qiagen, UK). cDNA was prepared for the RT2 PCR Array 96-well plate us-
ing RT2 SYBR Green ROX qPCR Mastermix and the array analyzed using
the Aligent Mx3005p qPCR system, with the thermal profile set to run one
cycle at 95 °C for 10 min, 95 °C for 15 s, 55 °C for 35 s, and 72 °C for 30 s
with 40 cycles. Fold change was calculated by first normalizing TIPS film
and control film (TE) quantification cycle (Cq) values from their respective
housekeeping gene values (HE) (TE−HE=ΔCTE). Nontreatment control
(TC) Cq values were normalized from housekeeping control values (HC)
(TC − HC = ΔCTC). The difference between the test and nontreatment
control Cq values was calculated (ΔCTE − ΔCTC = ΔΔCt) and expressed
fold change was determined (2 − ΔΔCt).
Histological Analysis: Leg muscle tissues were fixed in neutral buffered
formalin solution (4%) and processed into Paraplast X-TRA low-
temperature paraffin wax. Tissue sections were stained with hematoxylin
and eosin (H&E) or immunostained for using anti-Von Willebrand fac-
tor (VWF) antibody (Ab11713, Abcam, UK) to identify blood vessels in
the tissue sections. The stained tissue sections were imaged using a
Nanozoomer 2.0-HT (Hamamatsu, UK) digital slide scanner. The number
of positively stained blood was counted in 1 mm2 areas of tissue taken
from five fields of view in each tissue section. Manual vessel counting was
performed individually by three blinded observers.
Statistical Analysis: Data were analyzed using the GraphPad Prism
(version 8.0), as indicated in the figure legends. Mean values were
plotted with standard deviation. One-way analysis of variance (ANOVA)
or two-way ANOVA with Tukey multiple comparisons testing was used to
compare differences between two or more groups. Mann–Whitney test
was used to analyze differences between two independent nonparametric
data sets.
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